IQVIA HOLDINGS INC

IQVIA faces AI‑driven disruption from GPT‑Rosalind while eyeing growth in RWE and partner launches like Foundayo; its EPS surge and strategic M&A plans promise resilience in pharma’s shifting landscape.

IQVIA shares dip after AI‑drug‑discovery buzz, but the firm’s RWE and trial‑support strengths keep analysts neutral on its valuation.

IQVIA’s real‑world data shows INGREZZA outperforms AUSTEDO XR in treatment persistence and fewer switches for tardive dyskinesia, offering clinicians and payers evidence‑based insights.

Oakworth Capital’s purchase of 107 IQVIA shares shows investors still trust the company’s real‑world data and analytics to drive drug development, regulatory approvals, and generic launches across cardiology, oncology and infectious diseases.

IQVIA Holdings leads health‑data analytics, empowering pharma with real‑world insights for drug development, regulatory success, and resilient supply chains across a $2.6 trillion global market.

IQVIA’s AI strategy faces scrutiny as TD Cowen cuts its target, while a partnership with Isdin could unlock consumer‑health growth – can the company monetize AI amid regulatory pressure?

IQVIA Holdings’ analyst buzz: bullish growth‑fund buy, mixed bank targets, and a data‑science edge that investors eye for next‑quarter earnings.

IQVIA Q4 2025 earnings outlook: analysts predict modest revenue growth but stronger EPS; institutional investors shift positions amid early‑February price moves.

IQVIA’s share price climbs to the upper‑mid $230s, driven by a positive earnings outlook and a data‑driven clinical development strategy that blends real‑world evidence with molecular biology.

IQVIA Holdings Inc. boosts earnings with AI‑driven market‑access tools and growing clinical‑trial services, targeting a 45% market share and $1.2 bn 2024 revenue.